Privacy Policy
Start Here
Research
IPO & Public Offerings
Economy & Macro
Latest
Stock Market
Market Education
Energy & Commodities
Capital Markets
Federal Reserve & Rates
About
Contact

apogee therapeutics

AbbVie Buys Apogee for $10.9B; ABBV Pops 6%

September 12, 2026June 22, 2026 by Bruno M.

AbbVie agreed to buy Apogee Therapeutics for $10.9B all-cash at a 49% premium, adding IL-13 candidate zumilokibart to challenge Dupixent. ABBV rose 6%.

Categories Capital Markets Tags abbvie, apogee therapeutics, atopic dermatitis, immunology pipeline, pharma m&a, stock market

Search

Explore ECMSource

New here? Begin with our guide to the site, then explore the subjects that match what you want to understand.

Start Here
Market Education
Stock Market
Capital Markets
Federal Reserve & Rates

Subscribe to Our Newsletter

Please leave this field empty

Oh hi there 👋
It’s nice to meet you.

Sign up to receive awesome content in your inbox, every month.

We don’t spam! Read our privacy policy for more info.

Check your inbox or spam folder to confirm your subscription.

Privacy Policy
Editorial Policy
Corrections Policy
Financial Disclaimer
Contact
About Bruno M.
Investor Tools